Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Barcenas, CH; A. Hurvitz, Sara; A. Di Palma, Jack; Bose, Ron; Jo Chien, A.; Iannotti, Nicholas; Marx, Gavin; Brufsky, Adam; M. Litvak, Anya; Ibrahim, Elsayed; H. Álvarez, Ricardo; Ruíz‐Borrego, Manuel; Chan, Nancy; Manalo, Yvonne; Kellum, A.; Trudeau, Maureen; P. Thirlwell, Michael; García Saenz, J.; Hunt, Daniel; Bryce, Richard; McCulloch, Leanne; S. Rugo, Hope; Tripathy, Debu; Chan, Arlene; Carcas, Lauren; Castrellon, Aurelio; King Chung Chan, Derwin; Cheong, K.; Ock Choi, Byung; P. Coleman, Michel; Conlin, Alison; Dichmann, Robert; H. Ellison, David; Erickson, Nicholette; Gore, Ira; Hansen, Vincent; B Huang, D; Hufnagel, David; Kass, Frederic; D. Kendall, Stephan; Kozloff, Mark; Lawler, W; Nahum, Kelly; Pistilli, Barbara; Reyes, Eduardo; Seeger, Janell; A. Somer, Robert; Chiu, Elizabeth; W. Thomas, Gary; H. R. Tkaczuk, Katherine; Vaziri, Irfan; L. Wade, James; Wilkinson, M.

doi:10.1016/j.annonc.2020.05.012

Public

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Published in Annals of Oncology • May 25, 2020

Authors:

CH Barcenas

Sara A. Hurvitz

Jack A. Di Palma

Abstract

BACKGROUND: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxis was mandated, grade 3 diarrhea was observed in 40%...

Subject

Medicine

Neratinib

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!